

## APPOINTMENT OF SHORE CAPITAL AS JOINT BROKER

Released : 19 May 2017 07:00

RNS Number : 5818F  
Oxford BioDynamics PLC  
19 May 2017

**19 May 2017**

**Oxford BioDynamics Plc**  
("OBD" or the "Company")

### **Appointment of Shore Capital as Joint Broker**

Oxford BioDynamics Plc (AIM: OBD), a revenue-generating biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to announce the appointment of Shore Capital Stockbrokers Limited ("Shore Capital") as joint broker to the Company, with immediate effect.

#### **For further details contact:**

**Oxford BioDynamics Plc** **+44 (0)1865 518910**  
Christian Hoyer Millar, CEO  
Katie Long, CFO

**Stifel Nicolaus Europe Limited** **+44 (0)20 7710 7600**  
**Nominated Advisor and Broker**  
David Arch  
Jonathan Senior  
Peter Lees  
Ben Maddison

**Shore Capital** **+44 (0)20 7408 4090**  
**Joint Broker**  
Bidhi Bhoma  
Edward Mansfield

**FTI Consulting** **+44 (0)20 3727 1000**  
**Financial Public Relations Advisor**  
Julia Phillips  
Brett Pollard  
Natalie Garland-Collins

#### **Notes for Editors**

##### **About Oxford BioDynamics Plc**

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue-generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, *EpiSwitch*<sup>™</sup>, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, *EpiSwitch*<sup>™</sup> can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re-positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit [www.oxfordbiodynamics.com](http://www.oxfordbiodynamics.com).

This information is provided by RNS  
The company news service from the London Stock Exchange

END

APPOKFDPNBKDBPD